Kailera Therapeutics, Inc. (NASDAQ:KLRA) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) have been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $42.75.

A number of analysts have recently issued reports on KLRA shares. Weiss Ratings initiated coverage on Kailera Therapeutics in a report on Friday, August 14th. They issued a “sell (d)” rating for the company. Wall Street Zen lowered Kailera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th.

Kailera Therapeutics Price Performance

NASDAQ:KLRA opened at $12.83 on Monday. Kailera Therapeutics has a 1-year low of $12.36 and a 1-year high of $28.23. The company has a fifty day moving average of $17.03. The firm has a market cap of $1.66 billion and a price-to-earnings ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35). On average, analysts anticipate that Kailera Therapeutics will post -3.89 EPS for the current year.

Institutional Investors Weigh In On Kailera Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tidal Investments LLC acquired a new stake in shares of Kailera Therapeutics during the 2nd quarter valued at $309,000. Squarepoint Ops LLC purchased a new stake in shares of Kailera Therapeutics during the second quarter worth $993,000. Frazier Life Sciences Management L.P. acquired a new stake in Kailera Therapeutics during the second quarter valued at $24,233,000. Wellington Management Group LLP purchased a new position in Kailera Therapeutics in the second quarter valued at about $64,308,000. Finally, Atlas Venture Life Science Advisors LLC purchased a new position in Kailera Therapeutics in the second quarter valued at about $113,923,000.

Kailera Therapeutics Company Profile

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company’s programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders.

Kailera’s lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use.

The company’s operations are centered on the development of therapies for global markets.